Heterocyclic Compounds

Matches 51 - 100 out of 8,175	< 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 >

Document	Document Title
WO/2024/011414A1	REACTION METHOD FOR SECONDARY AMINE AND O-DIIODOBENZENE Disclosed in the present invention is a reaction method for secondary amine and o-diiodobenzene, comprising: reacting secondary amine with o-diiodobenzene in the presence of an alkali metal hydride or a Grignard reagent to complete the r...
WO/2024/015497A1	TYROSINE KINASE 2 INHIBITORS AND USES THEREOF This disclosure relates to compounds of Formula (I) or pharmaceutically acceptable salts thereof, in which all of the variables in Formula (I) are as defined in the application. The compounds of this disclosure are capable of inhibiting ...
WO/2024/011294A1	ANTI-GIARDIAL COMPOUNDS The present disclosure relates to compounds that find application as therapeutics. In particular, the disclosure relates to compounds of Formula (I) or Formula (II) and their pharmaceutically acceptable salt, solvates, or stereoisomers t...
WO/2024/015251A1	INHIBITORS OF HPK1 AND METHODS OF USE THEREOF Disclosed herein are compounds that are Hematopoietic Progenitor Kinase 1 (HPK1) inhibitors having a structure according to Formula I, and compositions containing those compounds. Methods of preparing the compounds, and methods of using ...
WO/2024/010762A1	C-MYC MRNA TRANSLATION MODULATORS AND USES THEREOF IN THE TREATMENT OF CANCER The present invention relates to novel c-MYC mRNA translation modulators, composition and methods of preparation thereof, and uses thereof in the treatment of cancer.
WO/2024/010761A1	C-MYC MRNA TRANSLATION MODULATORS AND USES THEREOF IN THE TREATMENT OF CANCER The present invention relates to novel c-MYC mRNA translation modulators, composition and methods of preparation thereof, and uses thereof in the treatment of cancer.
WO/2024/009206A1	A PROCESS FOR THE PREPARATION OF EDOXABAN AND ITS INTERMEDIATES The present invention relates to an efficient and industrially advantageous process for the preparation of Edoxaban of Formula-I or salt thereof. The present invention also relates to a process for preparation of Edoxaban intermediates n...
WO/2024/008834A1	MACROCYCLE COMPOUNDS USEFUL AS KRAS INHIBITORS The present invention relates to compounds of formula (I), wherein R1 to R6, A1 and A2 are as described herein, and their pharmaceutically acceptable salt thereof, and compositions including the compounds and methods of using the compoun...
WO/2024/007997A1	CRYSTAL FORM OF PYRIDONE POLYCYCLIC DERIVATIVE AND PREPARATION METHOD THEREFOR Disclosed in the present invention are a crystal form of a pyridone polycyclic derivative and a preparation method therefor, and particularly a crystal form of a compound as represented by formula (I) and a preparation method therefor.
WO/2024/006559A1	MODULATORS OF NLRP3 INFLAMMASOME AND RELATED PRODUCTS AND METHODS Compounds are provided for inhibiting NLRP3 inflammasome generally, or for treating a NLRP3 inflammasome dependent condition more specifically, by contacting the NLRP3 inflammasome or administering to a subject in need thereof, respectiv...
WO/2024/003533A1	PROTACS FOR TARGETED DEGRADATION OF KAT2A AND KAT2B FOR THE TREATMENT OF CANCER The present invention relates to bifunctional compounds (PROTACs) of formula (I) that target the degradation of KAT2A and KAT2B, their manufacture, pharmaceutical compositions comprising the compounds and the compounds for use as medicam...
WO/2024/005556A1	Compounds, pharmaceutical compositions containing them and their medical use for the treatment or prevention of vascular diseases The present disclosure provides compounds capable of exhibiting effects similar to those of 2-Cys-peroxyredoxin (2-Cys-Prx) in the body with excellent pharmacological effects and reduced side effects such as reduced cytotoxicity, and pha...
WO/2023/250017A1	COMPOUNDS FOR TREATING INFECTIONS Disclosed herein are compositions and methods for treating a Salmonella infection. Disclosed herein are compositions and methods for inhibiting FraB in Salmonella. Disclosed herein are methods of increasing 6-phospho-fructose-aspartate w...
WO/2023/247596A1	PYRAZOLOTHIAZOLE CARBOXAMIDES AND THEIR USES AS PDGFR INHIBITORS The disclosure is directed to compounds of formula (I) and pharmaceutically acceptable salts thereof. Pharmaceutical compositions comprising compounds of formula (I), as well as methods of their use and preparation, are also described.
WO/2023/247590A1	TRIAZOLOPYRIDINE AND BENZOISOXAZOLE CARBOXAMIDES AND THEIR USES AS PDGFR INHIBITORS The disclosure is directed to compounds of formula (I), and pharmaceutically acceptable salts thereof. Pharmaceutical compositions comprising compounds of formula (I), as well as methods of their use and preparation, are also described.
WO/2023/246839A1	SALT OF THIENO[2,3-D]IMIDAZOLE COMPOUND, CRYSTAL FORM THEREOF AND PHARMACEUTICAL USE THEREOF The present invention provides a salt of a compound with GLP-1R agonist activity, as represented by formula (I), and/or a crystal form, and preparation and pharmaceutical use, wherein a pharmaceutically acceptable salt is selected from a...
WO/2023/246925A1	ESTER COMPOUNDS AND USE THEREOF Disclosed in the present invention are compounds or pharmaceutically acceptable salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers or isotope labeled compounds thereof. The compounds are as shown in formula (I)....
WO/2023/241137A1	NITROGEN-CONTAINING COMPOUND, ORGANIC ELECTROLUMINESCENT APPARATUS, AND ELECTRONIC DEVICE The present application relates to the technical field of organic electroluminescent materials, and provides a nitrogen-containing compound, and an organic electroluminescent apparatus and an electronic device comprising same. The nitrog...
WO/2023/241136A1	HETEROCYCLIC COMPOUND, ORGANIC ELECTROLUMINESCENT APPARATUS, AND ELECTRONIC DEVICE The present application relates to the technical field of organic electroluminescent materials, and provides a heterocyclic compound, and an organic electroluminescent apparatus and an electronic device comprising same. The heterocyclic ...
WO/2023/240134A1	SUBSTITUTED 3,4-DIHYDROISOQUINOLIN-1(2H)-ONE DERIVATIVES AND RELATED USES The present disclosure relates to compounds of Formula (I): and to their pharmaceutically acceptable salts, pharmaceutical compositions, methods of use, and methods for their preparation. The compounds disclosed herein are useful for inh...
WO/2023/239768A1	TRICYCLIC TRIAZOLO COMPOUNDS AS DGK INHIBITORS The present application provides tricyclic triazolo compounds I that modulate the activity of diacylglycerol kinase (DGK), which are useful in the treatment of various diseases, including cancer.
WO/2023/239729A1	PYRIDINAMINE DERIVATIVES AND THEIR USE AS POTASSIUM CHANNEL MODULATORS The present disclosure is directed to compounds of Formula (I): wherein m, n, Y, R1, R2, R3, R4 and R5 are each as described herein, as stereoisomers, enantiomers or tautomers thereof or mixtures thereof; or pharmaceutically acceptable s...
WO/2023/232966A1	MACROCYCLIC OREXIN RECEPTOR AGONISTS AND USES THEREOF Provided herein are compounds of Formula (I), (I), or pharmaceutically acceptable salt thereof, wherein m, n, p, A1, A2, A3, A4, L, R1, R2, R3, R4, Formula (II), (II), V, X, Y and Z are defined herein. Also provided herein are pharmaceut...
WO/2023/232776A1	HALOINDOLE MACROCYCLIC COMPOUNDS FOR THE TREATMENT OF CANCER The present invention relates to compounds of formula (I), wherein R1 to R7, A1 and A2 are as described herein, and their pharmaceutically acceptable salt thereof, and compositions including the compounds and methods of using the compounds.
WO/2023/233130A1	CD73 INHIBITOR COMPOUNDS The present invention relates to compounds of formula I shown below: wherein R1, X2, X3, X4, X5, X6, X7, X8 and X9 are each as defined in the application. The present invention also relates to processes for the preparation of these compo...
WO/2023/227946A1	TYK2 INHIBITORS AND USES THEREOF Described herein are compounds that are TYK2 inhibitors, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, disease...
WO/2023/225041A1	RIPK1 INHIBITORS AND METHODS OF USE Described herein are compounds of Formula I or a pharmaceutically acceptable salt thereof. The compounds of Formula I act as RIPK1 inhibitors and can be useful in preventing, treating or acting as a remedial agent for RIPK1-related disea...
WO/2023/223346A1	AN IMPROVED PROCESS FOR THE PREPARATION OF EDOXABAN INTERMEDIATE The present invention relates to an improved process for the preparation of Edoxaban intermediate and further preparation of Edoxaban or its pharmaceutically acceptable salts.
WO/2023/224981A1	HSD17B13 INHIBITORS AND USES THEREOF Described herein are HSD17B13 inhibitors and pharmaceutical compositions comprising said inhibitors. The subject compounds and compositions are useful for the treatment of liver disease, metabolic disease, or cardiovascular disease, such...
WO/2023/217230A1	KINESIN KIF18A INHIBITOR AND USE THEREOF The present invention provides a KIF18A inhibitor and a method for synthesizing same. The compound of the present invention can regulate KIF18A protein to influence the cell cycle and the cell proliferation process, so as to treat cancer...
WO/2023/218023A1	THIAZOLOARYL-METHYL SUBSTITUTED CYCLIC HYDRAZINE-N-CARBOXAMIDE DERIVATIVES The present invention relates to compounds of the formula (I) Formula (I) wherein Ar1, R1, R2, R3, X1, X2, Y, and Z are as described in the description, to their preparation, to pharmaceutically 5 acceptable salts thereof, and to their u...
WO/2023/217906A1	PYRROLIDINONE DERIVATIVES AS INHIBITORS OF NF KAPPA B INDUCING KINASE The present disclosure relates to compounds of Formula (I) that inhibit NIK and pharmaceutical compositions comprising such compounds and methods of using the same. These compounds and pharmaceutical compositions are useful for preventin...
WO/2023/215494A1	THIOPHENE ULK1/2 INHIBITORS AND THEIR USE THEREOF Described herein are compounds that are ULK1/2 inhibitors and their use in the treatment of disorders such as cancers.
WO/2023/164257A9	COMPOSITIONS AND METHODS FOR INHIBITING FSP1 Provided herein are methods of inhibiting FSP1 and using FSP1 inhibitors as therapeutics for cancer.
WO/2023/215220A1	MACROCYCLIC INHIBITORS OF ATP CITRATE LYASE The present disclosure provides, in part, compounds of formula (I), or a stereoisomer and/or a pharmaceutically acceptable salt thereof, wherein the variables are as defined herein; pharmaceutical compositions comprising the compounds; a...
WO/2023/215404A1	SALTS AND POLYMORPHS OF CERTAIN MCL-1 INHIBITORS The present disclosure relates salts and the crystalline forms of certain 3',4,4',5-tetrahydro-2H,2'H-spiro[benzo[b][1,4]oxazepine-3,1 '-naphthalene] derivatives as well as pharmaceutical formulations and therapeutic uses thereof. The pr...
WO/2023/215449A1	TETRAHYDROISOQUINOLINE HETEROBIFUNCTIONAL BCL-XL DEGRADERS This disclosure provides compounds of Formula (I) or pharmaceutically acceptable salts thereof, that induce degradation of a BCL-XL protein. These are useful, for example, for treating a cancer in a subject (e.g., a human). This disclosu...
WO/2023/207746A1	ASYMMETRIC DONOR-RECEPTOR TYPE NEAR-INFRARED REGION II PROBE MOLECULE, METHOD FOR PREPARING SAME, AND USE THEREOF Provided are an asymmetric donor-receptor type near-infrared region II probe molecule, a method for preparing same, and use thereof. The probe molecule is represented by the following general formula (1). The emission spectrum of the pro...
WO/2023/207881A1	COMPOUNDS, PREPARATION METHODS AND USES THEREOF Provided herein are novel compounds, for example, compounds having a Formula A, B, C, D, E, or F, or a pharmaceutically acceptable salt thereof. Also provided herein are methods of preparing the compounds and methods of using the compoun...
WO/2023/212239A1	COMPOSITIONS USEFUL FOR MODULATING SPLICING Described herein are compounds of formula (I) that modulate splicing of a pre-mRNA, encoded by genes, and methods of treating diseases and conditions associated with gene expression or activity of proteins encoded by genes, such a diseas...
WO/2023/212549A1	TRICYCLIC PYRIDONES AND PYRIMIDONES Compounds with KRAS G12C inhibitory active are disclosed and methods of using the same to treat a cancer comprising a K-Ras G12C mutation.
WO/2023/212237A1	COMPOSITIONS USEFUL FOR MODULATING SPLICING Described herein are compounds of Formula (I) that modulate splicing of a pre-mRNA, encoded by genes, and methods of treating diseases and conditions associated with gene expression or activity of proteins encoded by genes, such a diseas...
WO/2023/210569A1	NOVEL COMPOUND, CONJUGATED POLYMER AND METHOD FOR PRODUCING SAME, FILM FORMATION COMPOSITION, ORGANIC THIN FILM, AND ORGANIC SEMICONDUCTOR ELEMENT The compound according to the present disclosure is a compound represented by general formula (1).
WO/2023/212231A1	COMPOSITIONS USEFUL FOR MODULATING SPLICING Described herein are compounds of Formula (I) that modulate splicing of a pre-mRNA, encoded by genes, and methods of treating diseases and conditions associated with gene expression or activity of proteins encoded by genes.
WO/2023/210741A1	BENZOTRIAZOLE COMPOUND The present invention addresses the problem of providing a medicine capable of treating and/or preventing a disease associated with oxidative stress through the inhibition of a protein-protein interaction between Keap1 and Nrf2 to activa...
WO/2023/208124A1	PIPERIDINE CARBOXAMIDE AZAINDANE DERIVATIVE, METHOD FOR PREPARING SAME, AND USE THEREOF The present application relates to a substituted piperidine carboxamide azaindane derivative, a method for preparing same, and use of a pharmaceutical composition containing the derivative or a deuterated derivative in medicine. Specific...
WO/2023/212548A1	TRICYCLIC PYRIDONES AND PYRIMIDONES Compounds with KRAS G12C inhibitory active are disclosed and methods of using the same to treat a cancer comprising a K-Ras G12C mutation.
WO/2023/205701A1	MACROCYCLIC HETEROCYCLES AND USES THEREOF The present disclosure provides compounds and pharmaceutically acceptable salt thereof, and methods of using the same. The compounds and methods have a range of utilities as therapeutics, diagnostics, and research tools. In particular, t...
WO/2023/205366A1	SMALL MOLECULE MODULATORS OF GP130 SIGNALING PATHWAYS Disclosed herein are small molecule compounds, compositions, formulations, and methods of modulating gpl30. Compounds, compositions, and formulations described herein are capable of modulating pro-inflammatory, fibrotic and/or regenerati...
WO/2023/201780A1	METHOD FOR PREPARING QUINOLONE COMPOUND AND INTERMEDIATE THEREOF Provided is a method for preparing a quinolone compound and an intermediate thereof, particularly, a method for preparing quinolone and a pharmaceutical quinolinone intermediate. Specifically, provided are a method for preparing a compou...

Matches 51 - 100 out of 8,175	< 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 >